Drug class
Peripheral aromatic L-amino-acid (DOPA) decarboxylase inhibitor
Mechanism of action
Inhibits peripheral DOPA decarboxylase and does not appreciably enter the central nervous system. When co-administered with levodopa, it reduces peripheral conversion of levodopa to dopamine, increasing levodopa availability to the CNS and reducing the required levodopa dose. Benserazide alone has no antiparkinson activity.
General use cases
- Used in combination with levodopa for Parkinsonism; benserazide is not an antiparkinson treatment by itself
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
